In recent years, targeted therapies exemplified by EGFR inhibitors, and immunotherapies, such as pembrolizumab hold immense potential in the treatment of advanced HNSCC [26, 44]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.